Repare Therapeutics Inc. (RPTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
RPTX POWR Grades
- Value is the dimension where RPTX ranks best; there it ranks ahead of 90.68% of US stocks.
- The strongest trend for RPTX is in Value, which has been heading up over the past 179 days.
- RPTX ranks lowest in Momentum; there it ranks in the 4th percentile.
RPTX Stock Summary
- Price to trailing twelve month operating cash flow for RPTX is currently 1,315.91, higher than 99.77% of US stocks with positive operating cash flow.
- For RPTX, its debt to operating expenses ratio is greater than that reported by only 8.75% of US equities we're observing.
- Revenue growth over the past 12 months for REPARE THERAPEUTICS INC comes in at 1,634.61%, a number that bests 99.49% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to REPARE THERAPEUTICS INC, a group of peers worth examining would be CMRX, OMGA, BOLT, ARCT, and PSTX.
- To dig deeper into the stock's financial statements, go to RPTX's page on browse-edgar?action=getcompany&CIK=0001808158.
RPTX Valuation Summary
- RPTX's EV/EBIT ratio is -18.6; this is 383.97% lower than that of the median Healthcare stock.
- Over the past 33 months, RPTX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for RPTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RPTX | 2023-03-17 | 3.1 | 1.5 | -14.2 | -18.6 |
| RPTX | 2023-03-16 | 3.2 | 1.5 | -14.7 | -19.7 |
| RPTX | 2023-03-15 | 3.2 | 1.5 | -14.4 | -19.0 |
| RPTX | 2023-03-14 | 3.3 | 1.6 | -15.0 | -20.2 |
| RPTX | 2023-03-13 | 3.3 | 1.5 | -14.8 | -19.9 |
| RPTX | 2023-03-10 | 3.1 | 1.5 | -14.1 | -18.4 |
RPTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RPTX has a Quality Grade of D, ranking ahead of 8.52% of graded US stocks.
- RPTX's asset turnover comes in at 0.002 -- ranking 426th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows RPTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.002 | 1 | -4.742 |
| 2021-03-31 | 0.001 | 1 | -4.174 |
| 2020-12-31 | 0.000 | 1 | -4.813 |
RPTX Price Target
For more insight on analysts targets of RPTX, see our RPTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $47.63 | Average Broker Recommendation | 1.45 (Moderate Buy) |
RPTX Stock Price Chart Interactive Chart >
RPTX Price/Volume Stats
| Current price | $9.70 | 52-week high | $18.68 |
| Prev. close | $10.08 | 52-week low | $8.06 |
| Day low | $9.57 | Volume | 78,800 |
| Day high | $10.20 | Avg. volume | 137,019 |
| 50-day MA | $11.34 | Dividend yield | N/A |
| 200-day MA | $13.26 | Market Cap | 408.16M |
Repare Therapeutics Inc. (RPTX) Company Bio
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.
Latest RPTX News From Around the Web
Below are the latest news stories about REPARE THERAPEUTICS INC that investors may wish to consider to help them evaluate RPTX as an investment opportunity.
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306CAMBRIDGE, Mass. & MONTREAL, March 14, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida. An AACR assigned |
Repare Therapeutics Full Year 2022 Earnings: US$0.69 loss per share (vs US$2.83 loss in FY 2021)Repare Therapeutics ( NASDAQ:RPTX ) Full Year 2022 Results Key Financial Results Revenue: US$131.8m (up by US$124.2m... |
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue EstimatesRepare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsCAMBRIDGE, Mass. & MONTREAL, February 28, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022. |
Shareholders in Repare Therapeutics (NASDAQ:RPTX) are in the red if they invested a year agoIt's easy to match the overall market return by buying an index fund. While individual stocks can be big winners... |
RPTX Price Returns
| 1-mo | -5.00% |
| 3-mo | N/A |
| 6-mo | -18.49% |
| 1-year | -26.29% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -34.06% |
| 2022 | -30.25% |
| 2021 | -38.51% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...